{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:01:00Z","timestamp":1788814860112,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urology.2025.10.011","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:11:09Z","timestamp":1760001069000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prescribing Patterns for Beta-3 Agonists and Anticholinergic Medications Used in Treatment of Overactive Bladder"],"prefix":"10.1016","volume":"208","author":[{"given":"Grace","family":"Khaner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Vurture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Malviya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Clearwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Laudano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.10.011_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11884-016-0344-9","article-title":"The burden of overactive bladder on US public health","volume":"11","author":"Reynolds","year":"2016","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"5 Suppl 1","key":"10.1016\/j.urology.2025.10.011_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","article-title":"Definition and epidemiology of overactive bladder","volume":"60","author":"Wein","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.10.011_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.10.011_bib4","first-page":"761","article-title":"Adverse events related to antimuscarinics and beta-3-agonist: \"real-life\" data from the Eudra-Vigilance Database","volume":"74","author":"DE Nunzio","year":"2022","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.urology.2025.10.011_bib5","first-page":"7","article-title":"Update on the management of overactive bladder: patient considerations and adherence","volume":"3","author":"Gomelsky","year":"2010","journal-title":"Open Access J Urol"},{"key":"10.1016\/j.urology.2025.10.011_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/gps.70036","article-title":"Risks of dementia associated with anticholinergic medication compared to beta-3 agonist among older patients with overactive bladder in Japan: the LIFE study","volume":"40","author":"Okita","year":"2025","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.urology.2025.10.011_bib7","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/nau.25040","article-title":"Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population","volume":"41","author":"Johnson","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2025.10.011_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00345-025-05595-4","article-title":"Pharmacotherapy for overactive bladder syndrome and the risk of incident dementia","volume":"43","author":"Sheyn","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.10.011_bib9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/bph.14921","article-title":"\u03b2(3) Adrenoceptor-induced cholinergic inhibition in human and rat urinary bladders involves the exchange protein directly activated by cyclic AMP 1 favoring adenosine release","volume":"177","author":"Silva","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.urology.2025.10.011_bib10","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/nau.25532","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"43","author":"Cameron","year":"2024","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2025.10.011_bib11","unstructured":"Medicare Provider Type Glossary. Center for Medicare & Medicaid Services.\u00a0Accessed May 26, 2025. https:\/\/data.cms.gov\/resources\/medicare-provider-type-glossary."},{"key":"10.1016\/j.urology.2025.10.011_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/nau.25627","article-title":"Trends in overactive bladder therapy: associations between clinical care pathways, practice guidelines, and therapy utilization patterns","volume":"44","author":"Mohamud","year":"2025","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2025.10.011_bib13","doi-asserted-by":"crossref","first-page":"316.e1","DOI":"10.1016\/j.ajog.2023.05.024","article-title":"Characteristics of providers who prescribed only anticholinergic medications for overactive bladder in 2020","volume":"229","author":"Carr","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.urology.2025.10.011_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/SPV.0000000000001575","article-title":"Trends of overactive bladder and pharmacologic treatment among US women","volume":"31","author":"King","year":"2024","journal-title":"Urogynecology"},{"issue":"6 Suppl","key":"10.1016\/j.urology.2025.10.011_bib15","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.10.011_bib16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/JU.0000000000001440","article-title":"Persistence and adherence of anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis","volume":"205","author":"Song","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.10.011_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b2\u2083 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.10.011_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/SPV.0000000000001258","article-title":"Efficacy and safety of vibegron for the treatment of overactive bladder in women: a subgroup analysis from the double-blind, randomized, controlled EMPOWUR trial","volume":"29","author":"Newman","year":"2023","journal-title":"Urogynecology"},{"key":"10.1016\/j.urology.2025.10.011_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.10.011_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/SPV.0000000000001301","article-title":"Despite recommendations, anticholinergics account for the majority of prescriptions to treat overactive bladder in the United States","volume":"29","author":"Carr","year":"2023","journal-title":"Urogynecology"},{"key":"10.1016\/j.urology.2025.10.011_bib21","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00192-021-04736-8","article-title":"Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk","volume":"32","author":"Menhaji","year":"2021","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2025.10.011_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.euros.2025.03.013","article-title":"National trends in medication prescriptions for male lower urinary tract symptoms and erectile dysfunction: findings from the Norwegian Prescription Database","volume":"75","author":"Julieb\u00f8-Jones","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urology.2025.10.011_bib23","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1007\/s12325-023-02625-8","article-title":"Patient and clinician challenges with anticholinergic step therapy in the treatment of overactive bladder: a narrative review","volume":"40","author":"Dmochowski","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2025.10.011_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urology.2023.09.020","article-title":"Analyzing access and costs of oral medications for overactive bladder: uncovering disparities","volume":"183","author":"Shapiro","year":"2024","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.10.011_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/AOG.0000000000004279","article-title":"Rethinking second-line therapy for overactive bladder to improve patient access to treatment options","volume":"137","author":"Escobar","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.urology.2025.10.011_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016408","article-title":"Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review","volume":"7","author":"Fickweiler","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.urology.2025.10.011_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.urology.2023.11.021","article-title":"Factors influencing medication selection for management of overactive bladder: trends and insights from AUA quality registry","volume":"184","author":"Bowman","year":"2024","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urology.2025.10.011_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/heq.2025.0059","article-title":"Beyond the binary: advancing gender-inclusive data policy for health equity in the US National provider identifier System","volume":"9","author":"Jacobs","year":"2025","journal-title":"Health Equity"},{"key":"10.1016\/j.urology.2025.10.011_bib29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/UPJ.0000000000000506","article-title":"Stepping away from step therapy for overactive bladder: the role of urologists in advocating for step therapy reforms","volume":"11","author":"Frankel","year":"2024","journal-title":"Urol Pract"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525009604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525009604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:06:40Z","timestamp":1770372400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525009604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"alternative-id":["S0090429525009604"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.10.011","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing Patterns for Beta-3 Agonists and Anticholinergic Medications Used in Treatment of Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}